Pay vs Performance Disclosure - USD ($)

1 Months Ended

11 Months Ended

12 Months Ended

Jan. 26, 2024

Dec. 31, 2024

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Pay vs Performance Disclosure

Pay vs Performance Disclosure, Table

PAY VERSUS PERFORMANCE

In accordance with Item 402(v) of Regulation S-K, the Company is required to disclose pay versus performance by comparing compensation amounts previously reported for the last five calendar years to the SEC’s definition of “Compensation Actually Paid” for such years. Also as required by the SEC, this section compares Compensation Actually Paid to various measures used to gauge performance at SIGA. Compensation Actually Paid is a required disclosure item, the amount of which is calculated in accordance with SEC rules. Such measure was not incorporated into the philosophy and strategy of compensation-setting set forth in the “Compensation Discussion and Analysis” of this proxy statement.

Pay Versus Performance Table
Year			Summary Compensation Table Total for PEO1			Compensation Actually Paid to PEO2			Average Summary Compensation Table Total for Non-PEO Named Executive Officers3			Average Compensation Actually Paid to Non-PEOs Named Executive Officers4,			Value of initial fixed $100 investment based on:						Net Income
															Total Shareholder Return			Peer Group Total Shareholder Return5						Product Sales and Supportive Services Revenues6
2024			$4,588,317			$5,640,511			$1,412,611			$1,351,882			$159			$114			$59,214,216			$133,330,181
2023			$1,825,856			$1,825,856			$1,399,930			$1,373,478			$135			$115			$68,068,826			$130,668,209
2022			$1,738,912			$1,738,912			$993,871			$993,871			$164			$111			$33,904,806			$86,661,583
2021			$1,688,264			$1,688,264			$1,285,045			$1,269,045			$158			$125			$69,450,766			$126,802,536
2020			$1,639,090			$1,639,090			$1,280,950			$1,354,729			$152			$126			$56,342,010			$115,471,071

(1)
Amount included here is the amount in the “Total” column from the Summary Compensation Table (“SCT”) for the principal executive officer (“PEO”) for the applicable year. For 2020-2023, our PEO was Dr. Gomez. For 2024, our PEO was Dr. Gomez until his retirement effective January 26, 2024 and Dr. Nguyen for the remainder of the fiscal year.

(2)
In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Compensation Actually Paid to PEO:

Year			Reported Summary Compensation Table for PEO			Reported Value of Equity Awards			Total Equity Award Adjustments(a)			Compensation “Actually Paid” to PEO
2024			$4,588,317			$(2,715,848)			$3,768,042			$5,640,511
2023			$1,825,856			—			—			$1,825,856
2022			$1,738,912			—			—			$1,738,912
2021			$1,688,264			—			—			$1,688,264
2020			$1,639,090			—			—			$1,639,090

a)
The amounts added or deducted in calculating the total equity award adjustments are as follows:

Year			Year-End Fair Value of Equity Awards Granted During Applicable Year			Fair Value of Equity Awards Granted and Vested in the Applicable Year			Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End			Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year			Total Equity Value Reflected in Compensation Actually Paid
2024			$3,362,329			$405,713			—			—			$3,768,042
2023			—			—			—			—			—
2022			—			—			—			—			—
2021			—			—			—			—			—
2020			—			—			—			—			—

(3)
Amount included here is the average of the amounts in the “Total” column from the SCT for the applicable year for each of the other non-PEO NEOs. For 2024, our non-PEO NEOs were Mr. Luckshire, Dr. Hruby, Mr. Miller and Dr. Varma. For 2023, our non-PEO NEOs were: Mr. Luckshire, Dr. Hruby and Dr. Varma. For 2022, 2021 and 2020, our non-PEO NEOs were Mr. Luckshire, Dr. Hruby and Ms. Robin E. Abrams (former General Counsel and Chief Administrative Officer). The 2022 amount was impacted by the resignation of Ms. Abrams, effective April 18, 2022. The 2023 amount includes compensation paid to Dr. Varma, pro-rated based on his commencement date with the Company.

(4)
In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Average Total Compensation for the NEOs as a group for each year to determine the compensations “actually paid”.

Year			Reported Summary Compensation Table for Non-PEO NEOs			Average Reported Value of Equity Awards			Total Average Equity Award Adjustments(a)			Average Compensation “Actually Paid” to Non-PEO NEOs
2024			$1,412,611			$(304,473)			$243,744			$1,351,882
2023			$1,399,930			$(283,333)			$256,881			$1,373,478
2022			$993,871			—			—			$993,871
2021			$1,285,045			—			$(16,000)			$1,269,045
2020			$1,280,950			—			$73,779			$1,354,729

a)
The amounts added or deducted in calculating the total average equity award adjustments are as follows:

Year			Year-End Fair Value of Equity Awards Granted During Applicable Year			Change in Fair Value as of Year- End of Any Prior Year Awards that Remain Unvested as of Year-End			Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year			Total Equity Value Reflected in Compensation Actually Paid
2024			$199,336			$7,715			$36,693			$243,744
2023			$256,881			—			—			$256,881
2022			—			—			—			—
2021			—			—			$(16,000)			$(16,000)
2020			—			$44,445			$29,334			$73,779

(5)
The peer group, for purposes of this analysis, is the Nasdaq Biotechnology Index. The company’s stock performance relative to the Nasdaq Biotechnology Index is disclosed in the Company’s Form 10-K.

(6)
Product Sales and Supportive Services Revenues is a financial measure that is consistent with U.S. GAAP that is considered by the Company as part of its executive compensation program. The Compensation Committee reviews a variety of performance goals and metrics for the purpose of awarding compensation to executive officers that are consistent with the Company’s overall compensation philosophy and the long-term interests of its stockholders. Among these, the Compensation Committee has identified Product Sales and Supportive Services Revenues as the most important financial performance measure (that is not otherwise required to be disclosed in the table above) used by the Company to link compensation actually paid to its NEOs for the year ended December 31, 2024 to the Company’s performance.

Company Selected Measure Name

Product Sales and Supportive Services Revenues

Named Executive Officers, Footnote

(1)
Amount included here is the amount in the “Total” column from the Summary Compensation Table (“SCT”) for the principal executive officer (“PEO”) for the applicable year. For 2020-2023, our PEO was Dr. Gomez. For 2024, our PEO was Dr. Gomez until his retirement effective January 26, 2024 and Dr. Nguyen for the remainder of the fiscal year.

(3)
Amount included here is the average of the amounts in the “Total” column from the SCT for the applicable year for each of the other non-PEO NEOs. For 2024, our non-PEO NEOs were Mr. Luckshire, Dr. Hruby, Mr. Miller and Dr. Varma. For 2023, our non-PEO NEOs were: Mr. Luckshire, Dr. Hruby and Dr. Varma. For 2022, 2021 and 2020, our non-PEO NEOs were Mr. Luckshire, Dr. Hruby and Ms. Robin E. Abrams (former General Counsel and Chief Administrative Officer). The 2022 amount was impacted by the resignation of Ms. Abrams, effective April 18, 2022. The 2023 amount includes compensation paid to Dr. Varma, pro-rated based on his commencement date with the Company.

Peer Group Issuers, Footnote

(5)
The peer group, for purposes of this analysis, is the Nasdaq Biotechnology Index. The company’s stock performance relative to the Nasdaq Biotechnology Index is disclosed in the Company’s Form 10-K.

PEO Total Compensation Amount

$ 4,588,317

$ 1,825,856

$ 1,738,912

$ 1,688,264

$ 1,639,090

PEO Actually Paid Compensation Amount

$ 5,640,511

1,825,856

1,738,912

1,688,264

1,639,090

Adjustment To PEO Compensation, Footnote

(2)
In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Compensation Actually Paid to PEO:

Year			Reported Summary Compensation Table for PEO			Reported Value of Equity Awards			Total Equity Award Adjustments(a)			Compensation “Actually Paid” to PEO
2024			$4,588,317			$(2,715,848)			$3,768,042			$5,640,511
2023			$1,825,856			—			—			$1,825,856
2022			$1,738,912			—			—			$1,738,912
2021			$1,688,264			—			—			$1,688,264
2020			$1,639,090			—			—			$1,639,090

a)
The amounts added or deducted in calculating the total equity award adjustments are as follows:

Year			Year-End Fair Value of Equity Awards Granted During Applicable Year			Fair Value of Equity Awards Granted and Vested in the Applicable Year			Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End			Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year			Total Equity Value Reflected in Compensation Actually Paid
2024			$3,362,329			$405,713			—			—			$3,768,042
2023			—			—			—			—			—
2022			—			—			—			—			—
2021			—			—			—			—			—
2020			—			—			—			—			—

Non-PEO NEO Average Total Compensation Amount

$ 1,412,611

1,399,930

993,871

1,285,045

1,280,950

Non-PEO NEO Average Compensation Actually Paid Amount

$ 1,351,882

1,373,478

993,871

1,269,045

1,354,729

Adjustment to Non-PEO NEO Compensation Footnote

(4)
In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Average Total Compensation for the NEOs as a group for each year to determine the compensations “actually paid”.

Year			Reported Summary Compensation Table for Non-PEO NEOs			Average Reported Value of Equity Awards			Total Average Equity Award Adjustments(a)			Average Compensation “Actually Paid” to Non-PEO NEOs
2024			$1,412,611			$(304,473)			$243,744			$1,351,882
2023			$1,399,930			$(283,333)			$256,881			$1,373,478
2022			$993,871			—			—			$993,871
2021			$1,285,045			—			$(16,000)			$1,269,045
2020			$1,280,950			—			$73,779			$1,354,729

a)
The amounts added or deducted in calculating the total average equity award adjustments are as follows:

Year			Year-End Fair Value of Equity Awards Granted During Applicable Year			Change in Fair Value as of Year- End of Any Prior Year Awards that Remain Unvested as of Year-End			Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year			Total Equity Value Reflected in Compensation Actually Paid
2024			$199,336			$7,715			$36,693			$243,744
2023			$256,881			—			—			$256,881
2022			—			—			—			—
2021			—			—			$(16,000)			$(16,000)
2020			—			$44,445			$29,334			$73,779

Compensation Actually Paid vs. Total Shareholder Return

The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) cumulative total shareholder return on the Common Stock and cumulative total shareholder return on the stock of NASDAQ Biotech Composite Index for the last five completed fiscal years is shown in Figure 1.

Figure 1: Compensation Actually Paid versus Total Shareholder Return (“TSR”)

Compensation Actually Paid vs. Net Income

The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) net income of the Company for the last five completed fiscal years is shown in Figure 2.

Figure 2: Compensation Actually Paid versus Net Income

Compensation Actually Paid vs. Company Selected Measure

The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) product sales and supportive services revenues of the Company for the last five completed fiscal years is shown in Figure 3.

Figure 3: Compensation Actually Paid versus Product Sales and Supportive Services Revenues

Total Shareholder Return Vs Peer Group

The relationship between (1) compensation actually paid to the PEO and the average of compensation actually paid to NEOs other than the PEO and (2) cumulative total shareholder return on the Common Stock and cumulative total shareholder return on the stock of NASDAQ Biotech Composite Index for the last five completed fiscal years is shown in Figure 1.

Figure 1: Compensation Actually Paid versus Total Shareholder Return (“TSR”)

Tabular List, Table

List of Performance Measures

The Company utilizes other important financial measures to consider for compensation actually paid to its NEOs performance as set forth in the table below.

 

Total Product Sales and Supportive Services Revenues

Operating Income (Pre-Tax)

Total Revenues

International Sales Revenue

Net Income

Diluted Earnings per Share

Relative TSR

 

Total Shareholder Return Amount

$ 159

135

164

158

152

Peer Group Total Shareholder Return Amount

114

115

111

125

126

Net Income (Loss)

$ 59,214,216

$ 68,068,826

$ 33,904,806

$ 69,450,766

$ 56,342,010

Company Selected Measure Amount

133,330,181

130,668,209

86,661,583

126,802,536

115,471,071

PEO Name

Dr. Gomez

Dr. Nguyen

Dr. Gomez.

Dr. Gomez.

Dr. Gomez.

Dr. Gomez.

Equity Awards Adjustments, Footnote

a)
The amounts added or deducted in calculating the total equity award adjustments are as follows:

Year			Year-End Fair Value of Equity Awards Granted During Applicable Year			Fair Value of Equity Awards Granted and Vested in the Applicable Year			Change in Fair Value as of Year-End of Any Prior Year Awards that Remain Unvested as of Year-End			Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year			Total Equity Value Reflected in Compensation Actually Paid
2024			$3,362,329			$405,713			—			—			$3,768,042
2023			—			—			—			—			—
2022			—			—			—			—			—
2021			—			—			—			—			—
2020			—			—			—			—			—

a)
The amounts added or deducted in calculating the total average equity award adjustments are as follows:

Year			Year-End Fair Value of Equity Awards Granted During Applicable Year			Change in Fair Value as of Year- End of Any Prior Year Awards that Remain Unvested as of Year-End			Change in Fair Value as of the Vesting Date of Any Prior Year Awards that Vested During Applicable Year			Total Equity Value Reflected in Compensation Actually Paid
2024			$199,336			$7,715			$36,693			$243,744
2023			$256,881			—			—			$256,881
2022			—			—			—			—
2021			—			—			$(16,000)			$(16,000)
2020			—			$44,445			$29,334			$73,779

Measure:: 1

Pay vs Performance Disclosure

Name

Total Product Sales and Supportive Services Revenues

Measure:: 2

Pay vs Performance Disclosure

Name

Operating Income (Pre-Tax)

Measure:: 3

Pay vs Performance Disclosure

Name

Total Revenues

Measure:: 4

Pay vs Performance Disclosure

Name

International Sales Revenue

Measure:: 5

Pay vs Performance Disclosure

Name

Net Income

Measure:: 6

Pay vs Performance Disclosure

Name

Diluted Earnings per Share

Measure:: 7

Pay vs Performance Disclosure

Name

Relative TSR

PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ (2,715,848)

$ 0

$ 0

$ 0

$ 0

PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

3,768,042

0

0

0

0

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

3,362,329

0

0

0

0

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

0

PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

405,713

0

0

0

0

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

0

0

0

0

0

Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(304,473)

(283,333)

0

0

0

Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

243,744

256,881

0

(16,000)

73,779

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

199,336

256,881

0

0

0

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

7,715

0

0

0

44,445

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ 36,693

$ 0

$ 0

$ (16,000)

$ 29,334